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1. INTRODUCTION {#cam42250-sec-0005}
===============

Neoadjuvant chemoradiotherapy has become a promising treatment for patients with stage II or III esophageal cancer. Several studies have reported that its use has improved local control, progression free survival (PFS), and overall survival (OS) in comparison with surgery alone.[1](#cam42250-bib-0001){ref-type="ref"}, [2](#cam42250-bib-0002){ref-type="ref"}, [3](#cam42250-bib-0003){ref-type="ref"} Conventional fractionated radiotherapy (CFRT) is the most commonly used neoadjuvant option for esophageal cancer, but the efficacy and safety of preoperative hypofractionated radiotherapy (HFRT), which delivers a dose larger than 2 Gray (Gy) per fraction in a lower overall dose, has also been studied in some patients with esophageal cancer.[4](#cam42250-bib-0004){ref-type="ref"}, [5](#cam42250-bib-0005){ref-type="ref"} These studies have indicated that preoperative HFRT could improve the local control rate of esophageal cancer and potentially increase patient survival compared with surgery alone. However, existing research has only compared surgery alone with preoperative HFRT plus surgery. To the best of our knowledge, there has been no comparison of HFRT and CFRT for the neoadjuvant treatment of esophageal cancer, and the optimal dose‐fractionation schedule remains undefined. Therefore, this retrospective study aimed to investigate and compare the efficacy, safety, and costs of neoadjuvant HFRT and the standard CFRT regimen for esophageal cancer.

2. MATERIALS AND METHODS {#cam42250-sec-0006}
========================

2.1. Patients {#cam42250-sec-0007}
-------------

We retrospectively reviewed 110 patients with esophageal cancer who were treated with neoadjuvant chemoradiotherapy followed by surgery at authors^,^ institute from October 2002 to July 2017. Inclusion criteria were: (a) histologically or cytologically confirmed thoracic esophageal squamous cell carcinoma; (b) clinically stage II or III, as determined by the American Joint Committee on Cancer TNM 2002 staging system (version6.0)[6](#cam42250-bib-0006){ref-type="ref"}; (c) Karnofsky performance status ≥80; (d) patients underwent neoadjuvant chemoradiotherapy followed by esophagectomy. Exclusion criteria were: (a) patients who had received previous anti‐tumor treatment for esophageal cancer before neoadjuvant chemoradiotherapy; (b) patients who had insufficient follow‐up data; (c) patients who had previous malignancy or other concomitant malignant diseases. Current study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. A waiver of informed consent was requested, and this study was approved by authors^,^ institute.

Patients were divided into two treatment subgroups based on dose‐fractionation schedule of preoperative radiotherapy: (a) HFRT group; (b) CFRT group.

2.2. Preoperative treatment {#cam42250-sec-0008}
---------------------------

All patients received preoperative intensity‐modulated radiation therapy concurrent with chemotharpy. In the HFRT group, patients received a total dose of 30 Gy in 10 fractions over 2 weeks, five fractions per week. In the CFRT group, patients received a total dose of 40 Gy in 20 fractions over 4 weeks, five fractions per week. The radiotherapy was delivered with photon energies of 6‐10 MV. The gross tumor volume (GTV) was defined by the primary tumor and any positive regional lymph nodes, which were determined using all available information, including physical examination, endoscopy, endoscopic ultrasonography, and neck‐thorax‐abdomen CT. The clinical target volume (CTV) provided a 3 cm margin in the proximal and distal direction and a 0.5 cm‐1.0 cm radial margin around the GTV. The planning target volume was defined by including an additional 0.5 cm margin of the CTV for tumor motion and set‐up variations. Neoadjuvant chemotherapy was concomitantly administered in all patients at 3‐week intervals (2 cycles) and comprised either cisplatin with 5‐fluorouracil (PF) or cisplatin with taxane (TP).

2.3. Surgery {#cam42250-sec-0009}
------------

Surgery was performed 3‐8 weeks after completion of radiotherapy. Esophagectomy and standard regional lymph node dissection, including two‐field or three‐field dissection, was performed. A group of pathologists examined the entire specimen with primary and dissected lymph nodes and reported the tumor type and extension, proximal and distal resection margins and lymph node status. Pathological downstaging was defined as a reduction in the clinical T or N stage compared with the pathological T or N stage prior to the start of neoadjuvant treatment. Pathologic complete response (pCR) was defined as no evidence of residual tumor cells in the primary site as well as in the resected regional lymph nodes.

2.4. Outcomes {#cam42250-sec-0010}
-------------

Overall survival was calculated from the date of initial diagnosis to the date of death or last follow‐up. The time interval between initial diagnosis and local, regional recurrence, distant metastasis, death from any cause or last follow‐up without recurrence and metastasis was defined as PFS. The toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). The radiotherapy and neoadjuvant treatment related time and costs were compared. The radiotherapy costs was calculated from the date of the radiation planning scan to the last radiotherapy treatment and included all associated radiation procedures including radiotherapy simulation, treatment plan generation, radiotherapy treatment, and image guidance. The total costs consisted of preoperative radiotherapy, chemotherapy, hospital stay charges, professional fees, imaging, all ensuing salvage and symptomatic supportive therapies, as incurred.

2.5. Statistical analyses {#cam42250-sec-0011}
-------------------------

Statistical analyses were performed using SPSS 20.0 (SPSS Inc, Chicago, IL, USA). We used the Kaplan‐Meier method to estimate OS and PFS, with the log‐rank test to ascertain significance. The categorical variables between groups were compared using Pearson\'s Chi square test or Fisher\'s exact test, if indicated. Univariate and multivariate analysis with the Cox proportional hazards model was used to investigate the effect of different factors on survival. Covariates included treatment group (CFRT vs HFRT), sex, age (≤60 years vs \>60 years), tumor location, KPS score (80 vs ≥90), clinical T‐stage (T1‐2 vs T3 vs T4), clinical N‐stage, chemotherapy regimens, pCR, and pathological downstaging. A two‐tailed *P*‐value less than 0.05 was considered statistically significant.

3. RESULTS {#cam42250-sec-0012}
==========

3.1. Patient characteristics {#cam42250-sec-0013}
----------------------------

The clinical characteristics of the participants in the HFRT group (n = 42) and the CFRT group (n = 68) are summarized in Table [1](#cam42250-tbl-0001){ref-type="table"}. There were no significant differences in any clinical features between the two treatment groups.

###### 

Baseline characteristics for patients in HFRT group vs CFRT group

  Characteristics                                   HFRT group (n = 42)   CFRT group (n = 68)   *P*
  ------------------------------------------------- --------------------- --------------------- -------
  Sex                                                                                           0.454
  Male                                              32                    57                     
  Female                                            10                    11                     
  Age, years                                                                                    0.539
  ≤60                                               29                    42                     
  \>60                                              13                    26                     
  Tumor location                                                                                0.960
  Upper thoracic                                    9                     14                     
  Middle thoracic                                   25                    43                     
  Lower thoracic                                    8                     11                     
  KPS score                                                                                     1.000
  ≥90                                               25                    40                     
  80                                                17                    28                     
  cT‐stage[a](#cam42250-note-0003){ref-type="fn"}                                               0.732
  T1‐2                                              3                     8                      
  T3                                                27                    41                     
  T4                                                12                    19                     
  cN‐stage[a](#cam42250-note-0003){ref-type="fn"}                                               0.426
  N0                                                19                    25                     
  N1                                                23                    43                     
  Chemotherapy regimens                                                                          
  TP                                                12                    27                    0.306
  PF                                                30                    41                     

Abbreviations: CFRT, conventional fractionated radiotherapy; HFRT, hypofractionated radiotherapy; KPS, Karnofsky performance status; PF, cisplatin with 5‐fluorouracil; TP, cisplatin with taxane.

AJCC 2002 staging system.

John Wiley & Sons, Ltd

3.2. Pathology {#cam42250-sec-0014}
--------------

In the HFRT group, 40 patients (95.2%) underwent R0 resection compared with 64 (94.1%) in the CFRT group (*P* = 1.000). pCR was achieved in 14 patients (33.3%) after HFRT and 24 patients (35.3%) after CFRT (*P* = 0.834). Regarding the distribution of pathologic stages, patients in the HFRT group underwent similar downstaging compared with the CFRT group (78.6% vs 83.8%, *P* = 0.612) (Table [2](#cam42250-tbl-0002){ref-type="table"}).

###### 

Distribution of pathologic stage groups after surgery

  Pathologic stage group   HFRT group (n = 42)   CFRT group (n = 68)   *P*
  ------------------------ --------------------- --------------------- -------
  pT‐stage                                                             0.338
  T0                       16                    30                     
  T1                       4                     10                     
  T2                       12                    9                      
  T3                       9                     18                     
  T4                       1                     1                      
  pN‐stage                                                             1.000
  N0                       25                    41                     
  N1                       17                    27                     
  pCR                      14 (33.3%)            24 (35.3%)            0.834
  Pathologic downstaging   33 (78.6%)            57 (83.8%)            0.612

Abbreviations: CFRT, conventional fractionated radiotherapy; HFRT, hypofractionated radiotherapy; pCR, pathologic complete response.

John Wiley & Sons, Ltd

3.3. Survival {#cam42250-sec-0015}
-------------

The median follow‐up across the whole study population was 33 months. Kaplan‐Meier analysis for OS and PFS revealed no significant difference between the groups. The median OS was 40.8 and 44.9 months in the HFRT and CFRT groups, respectively (*P* = 0.772; Figure [1](#cam42250-fig-0001){ref-type="fig"}). More specifically, the respective OS rates in the HFRT and CFRT group were 90.4% and 84.9% at 1 year, 54.8% and 57.7% at 3 years and 35.3% and 38.0% at 5 years. The median PFS was 32.7 months in the HFRT group compared with 35.4 months in the CFRT group (*P* = 0.785; Figure [2](#cam42250-fig-0002){ref-type="fig"}). As summarized in Table [3](#cam42250-tbl-0003){ref-type="table"}, multivariate analysis indicated that clinical N0 stage (*P* = 0.018), downstaging (*P* = 0.020) and pCR (*P* = 0.039) were independent predictors of a better OS (Table [3](#cam42250-tbl-0003){ref-type="table"}).

![Overall survival for patients in HFRT group vs CFRT group. CRFT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy](CAM4-8-3710-g001){#cam42250-fig-0001}

![Progression‐free survival for patients in HFRT group vs CFRT group. CRFT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy](CAM4-8-3710-g002){#cam42250-fig-0002}

###### 

Univariate and multivariate analysis demonstrating factors associated with OS

  Subgroup                Univariate analysis    Multivariate analysis                          
  ----------------------- ---------------------- ----------------------- ---------------------- -------
  Treatment group                                                                               
  CRFT                    1.00                                           1.00                    
  HFRT                    1.080 (0.639‐1.826)    0.772                   1.062 (0.609‐1.850)    0.833
  Sex                                                                                           
  Male                    1.00                                           1.00                    
  Female                  0.871(0.451‐1.682)     0.680                   0.541 (0.256‐1.144)    0.108
  Age, years                                                                                    
  ≤60                     1.00                                           1.00                    
  \>60                    0.814(0.456‐1.452)     0.486                   0.982 (0.509‐1.897)    0.958
  Tumor location                                                                                
  Upper thoracic          1.00                                           1.00                    
  Middle thoracic         0.730 (0.394‐1.350)    0.315                   0.567 (0.284‐1.129)    0.106
  Lower thoracic          0.924 (0.414‐2.063)    0.847                   0.559 (0.222‐1.405)    0.216
  KPS score                                                                                     
  80                      1.00                                           1.00                    
  ≥90                     0.787 (0.456‐1.356)    0.388                   0.799 (0.443‐1.439)    0.455
  Clinical T‐stage                                                                              
  T1‐2                    1.00                                                                   
  T3                      2.443 (0.747‐7.991)    0.139                   1.795 (0.923‐13.056)   0.356
  T4                      3.479 (1.010‐11.989)   0.048                   3.471 (1.133‐3.799)    0.066
  Clinical N‐stage                                                                              
  N0                      1.00                                           1.00                    
  N1                      1.794 (1.028‐3.130)    0.040                   2.075 (1.133‐3.799)    0.018
  Chemotherapy regimens                                                                         
  PF                      1.00                                                                   
  TP                      0.859 (0.475‐1.553)    0.614                   0.806 (0.429‐1.515)    0.503
  pCR                                                                                           
  Yes                     1.00                                           1.00                    
  No                      2.483 (1.359‐4.535)    0.003                   2.012 (1.036‐3.908)    0.039
  Downstaging                                                                                   
  Yes                     1.00                                           1.00                    
  No                      2.810 (1.471‐5.370)    0.002                   2.332 (1.145‐4.752)    0.020

Abbreviations: CRFT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy; KPS, Karnofsky performance status; pCR, pathologic complete response; PF, cisplatin with 5‐fluorouracil; TP, cisplatin with taxane.

John Wiley & Sons, Ltd

3.4. Toxicities {#cam42250-sec-0016}
---------------

Table [4](#cam42250-tbl-0004){ref-type="table"} summarizes the haematological and non‐haematological toxicities observed during neoadjuvant chemoradiotherapy. Leukopenia was the most common grade 3 or 4 adverse event. Overall, 13 of the 42 patients who received HFRT (31.0%) developed grade 3 or 4 leukopenia compared to 25 of the 68 patients who received CFRT (36.8%) (*P* = 0.546). However, neither the adverse events during chemoradiotherapy nor the postoperative complications differed significantly between the two groups (Table [4](#cam42250-tbl-0004){ref-type="table"}). No deaths occurred within 30 days after surgery in either group.

###### 

Adverse events during chemoradiotherapy and postoperative complications

                                            HFRT group (n = 42)   CFRT group (n = 68)   *P*
  ----------------------------------------- --------------------- --------------------- -------
  Adverse events during chemoradiotherapy                                               
  Leukopenia                                                                             
  Any grade                                 36 (85.7%)            61 (89.7%)            0.555
  ≥Grade 3                                  13 (31.0%)            25 (36.8%)            0.546
  Anemia                                                                                 
  Any grade                                 22 (52.4%)            38 (55.9%)            0.844
  ≥Grade 3                                  2 (4.8%)              5 (7.4%)              0.706
  Thrombocytopenia                                                                       
  Any grade                                 12 (28.6%)            16 (23.5%)            0.653
  ≥Grade 3                                  2 (4.8%)              3 (4.4%)              1.000
  Anorexia/Vomiting                                                                      
  Any grade                                 19 (45.2%)            33 (48.5%)            0.845
  ≥Grade 3                                  1 (2.4%)              3 (4.4%)              1.000
  Radiation esophagitis                                                                  
  Any Grade                                 16 (38.1%)            22 (32.4%)            0.680
  ≥Grade 3                                  2 (4.8%)              2 (2.9%)              1.000
  Radiation pneumonitis                                                                  
  Any grade                                 6 (14.3%)             13 (19.1%)            0.609
  ≥Grade 3                                  0 (%)                 1 (1.5%)              1.000
  Postoperative complications                                                           
  Anastomotic leakage                       5 (11.9%)             5 (7.4%)              0.501
  Hemorrhage                                1 (2.4%)              0 (0.0%)              0.385
  Chylothorax                               1 (2.4%)              1 (1.5%)              1.000
  Pulmonary infection                       5 (11.9%)             12 (17.6%)            0.588
  Pleural effusion                          4 (9.5%)              9 (13.2%)             0.778
  Incision infection                        2 (4.8%)              2 (2.9%)              0.635
  Arrhythmia                                2 (4.8%)              5 (7.4%)              0.706
  Injury of recurrent nerve                 1 (2.4%)              1 (1.5%)              1.000

Abbreviations: CRFT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy.

John Wiley & Sons, Ltd

3.5. Treatment time and cost analysis {#cam42250-sec-0017}
-------------------------------------

The median times for preoperative treatment were 69.00 ± 13.50 and 80.46 ± 11.74 days in the HFRT and the CFRT groups, respectively (*P* = 0.000). It took a median of 16.71 ± 4.22 days to deliver neoadjuvant radiotherapy in the HFRT group compared with 32.85 ± 5.09 days in the CFRT group (*P* = 0.000). (Table [5](#cam42250-tbl-0005){ref-type="table"}).

###### 

Treatment time and cost analysis

                                      HFRT group (n = 42)   CFRT group (n = 68)   *P*
  ----------------------------------- --------------------- --------------------- -------
  Radiotherapy time, days             16.71 ± 4.22          32.85 ± 5.09          0.000
  Preoperative treatment time, days   69.00 ± 13.50         80.46 ± 11.74         0.000
  Radiotherapy cost, yuan             14218.67 ± 5424.12    28750.94 ± 7093.25    0.000
  Preoperative total cost, yuan       23205.86 ± 5862.65    39170.38 ± 8752.78    0.000

Abbreviations: CRFT, conventionally fractionated radiotherapy; HFRT, hypofractionated radiotherapy.

John Wiley & Sons, Ltd

Table [5](#cam42250-tbl-0005){ref-type="table"} summarizes the average total and radiotherapy‐related costs for each group during neoadjuvant treatment. The average total costs for patients treated with HFRT were significantly less (23205.86 ± 5862.65 yuan) compared with that for those treated with CFRT (39170.38 ± 8752.78 yuan; *P* = 0.000). The average costs related to radiotherapy were also significantly lower in the HFRT group (14218.67 ± 5424.12 yuan) than in the CFRT group (28750.94 ± 7093.25 yuan; *P* = 0.000).

4. DISCUSSION {#cam42250-sec-0018}
=============

In recent years, the need for neoadjuvant chemoradiotherapy has increasingly been recognized in esophageal cancer. There are multiple advantages to this therapy. First, the local blood supply and oxygenation of a tumor is important for drug delivery in chemotherapy and sensitivity in radiotherapy, so these procedures are best performed when tumor blood vessels are not damaged by surgery. Second, neoadjuvant chemoradiotherapy can downstage tumors, improving their resectability and decreasing the rate of positive surgical margins. Third, the necrosis and fibrosis of tumor tissue after neoadjuvant chemoradiotherapy greatly reduces active tumor cells and the probability of tumor cells shedding, spreading, and planting during surgery, thereby reducing local recurrence rates. Compared with esophagectomy alone, several randomized studies have indicated that this neoadjuvant chemoradiotherapy improves pCR, locoregional control, and survival in patients with esophageal cancer undergoing esophagectomy.[1](#cam42250-bib-0001){ref-type="ref"}, [2](#cam42250-bib-0002){ref-type="ref"}, [7](#cam42250-bib-0007){ref-type="ref"}

Conventional fractionated radiotherapy has become the mainstay of preoperative radiotherapy in esophageal cancer. However, the extension of preoperative treatment time and the increase of treatment cost is an issue that must be considered. How can we reduce the treatment time and costs while maintaining the efficacy and safety? HFRT may provide us with a new strategy. It was postulated that a HFRT schedule that delivers doses larger than 2 Gy per fraction, but with a lower overall dose, improves dose escalation strategies to increase tumor control and helps maintain dose equivalence for tumor cure while decreasing the dose delivered to normal tissue.[8](#cam42250-bib-0008){ref-type="ref"}, [9](#cam42250-bib-0009){ref-type="ref"} There have been many studies showing the benefits of HFRT in lung cancer,[10](#cam42250-bib-0010){ref-type="ref"}, [11](#cam42250-bib-0011){ref-type="ref"} prostate cancer,[12](#cam42250-bib-0012){ref-type="ref"}, [13](#cam42250-bib-0013){ref-type="ref"} breast cancer,[14](#cam42250-bib-0014){ref-type="ref"}, [15](#cam42250-bib-0015){ref-type="ref"} advanced head and neck cancer [16](#cam42250-bib-0016){ref-type="ref"}, [17](#cam42250-bib-0017){ref-type="ref"} and locally advanced inoperative esophageal cancer.[18](#cam42250-bib-0018){ref-type="ref"}, [19](#cam42250-bib-0019){ref-type="ref"} Regarding preoperative HFRT, colorectal cancer is the most studied cancer, with research indicating that preoperative HFRT (also called short‐course radiotherapy) is as effective as conventional radiotherapy (also called long‐course radiotherapy) in terms of long‐term survival.[20](#cam42250-bib-0020){ref-type="ref"}, [21](#cam42250-bib-0021){ref-type="ref"}, [22](#cam42250-bib-0022){ref-type="ref"}

Prior to our study, only few studies focused on the use of preoperative HFRT followed by surgery in esophageal cancer. Walsh et al[4](#cam42250-bib-0004){ref-type="ref"} conducted a prospective, randomised trial comparing surgery alone and a combination of HFRT, chemotherapy and surgery. Patients assigned to the multimodal therapy received two courses of chemotherapy and a course of radiotherapy (40 Gy/15 fractions over 3 weeks), followed by surgery, and it was reported that pCR was achieved in 25% of patients who underwent multimodal therapy. The median OS among patients assigned to receive multimodal therapy was 16 months, compared with 11 months for those assigned to surgery alone (*P* \< 0.01). In another research, Wang et al[5](#cam42250-bib-0005){ref-type="ref"} reported their retrospective findings for 81 patients with esophageal squamous cancer; among whom 44 underwent preoperative HFRT with surgery and 47 underwent surgery alone. The patients who underwent preoperative HFRT showed a higher median OS compared with the patients who underwent surgery alone (24.0 months vs 18.0 months).

Although the previous studies of preoperative HFRT followed by surgery indicated that HFRT achieved better outcomes and acceptable toxicity rates compared with surgery alone in patients with resectable esophageal cancer, these trials had certain limitations. They only focused on comparing surgery alone with preoperative HFRT plus surgery, and none compared HFRT with CFRT. Moreover, each of these trials was reported over 20 years ago, and there have undoubtedly been marked improvements in surgical procedures, radiotherapy and chemotherapy over the ensuing 20 years. To the best of our knowledge, no report comparing the efficacies of preoperative HFRT and CFRT in the treatment of esophageal cancer is available.

In the present study, we compared the efficacies of concurrent chemotherapy with preoperative HFRT or CFRT for the treatment of stage II or III esophageal squamous cell cancer. The pCR rate of HFRT (33.3%) was comparable to that of CFRT (35.3%). Pathological downstaging rates were also comparable (*P* = 0.612) at 78.6% for HFRT and 83.8% for CFRT. Kaplan‐Meier analysis confirmed that there were no significant differences in median OS or PFS between the HFRT (40.8 and 32.7 months, respectively; *P* = 0.772) and CFRT (44.8 and 35.4 months, respectively; *P* = 0.785) groups. Therefore, our retrospective data indicated that HFRT is at least non‐inferior to CFRT in terms of the pCR, PFS and OS when treating esophageal cancer.

Given that the oesophagus is a hollow tubular structure, we must consider the potential for HFRT to produce serious side effects, such as esophageal stenosis, haemorrhage, perforation or fistula.[23](#cam42250-bib-0023){ref-type="ref"} Appropriate total and daily doses must be established for the safe use of HFRT. A phase I/II study of fraction dose escalation indicated that a daily dose of ≤5 Gy is comparatively suitable and tolerated in HFRT for esophageal carcinoma.[18](#cam42250-bib-0018){ref-type="ref"} A daily dose of 3 Gy is most often used for HFRT in locally advanced esophageal cancer. Ma et al reported relevant findings in 150 patients with thoracic esophageal squamous cell carcinoma (stage T2‐4, N0‐1, M0). Data were prospectively collected for 74 patients who underwent moderate HFRT (MHFRT) with a total dose of 54‐60 Gy in 18‐20 fractions for 3.5‐4 weeks and for 76 patients who underwent CFRT. No significant differences were observed in the incidences of grade 3 or higher acute toxicities (66.3% vs 50.0%, respectively) or of late complications (27.0% vs 22.4%, respectively) between the MHFRT and CFRT arms (*P* \> 0.05). A total of six treatment‐related deaths due to esophageal fistulas, pneumonia, cardiotoxicity, or hematological toxicity occurred in the MHFRT arm. Conversely, only two treatment‐related deaths occurred in the CFRT arm. The incidence rates of grade 3 or higher late esophageal complications, including stenosis, fistula or hemorrhage, were similar between the MHFRT and CFRT arms (18.9% vs 21.1%, respectively).[19](#cam42250-bib-0019){ref-type="ref"}

In our study, no significant differences were noted in the occurrence of CRT toxicities or of postoperative complications between the HFRT and CFRT groups, and no deaths occurred within 30 days after surgery. The overall rates of toxicity and treatment‐related deaths observed with HFRT were less compared with previous reports.[4](#cam42250-bib-0004){ref-type="ref"}, [5](#cam42250-bib-0005){ref-type="ref"}, [19](#cam42250-bib-0019){ref-type="ref"} The possible explanation for this is as follows: (a) total preoperative radiotherapy dose in the present study was lower than that used by either Ma et al[19](#cam42250-bib-0019){ref-type="ref"} or Walsh et al[4](#cam42250-bib-0004){ref-type="ref"} in their studies, (b) the area of the oesophagus that was subject to the highest radiation dose was resected during surgery, which greatly reduced the potential for radiation‐induced perforations or fistulae and (c) the use of intensity‐modulated radiotherapy in our study allowed the precise delivery of radiation to a target volume that contained only a limited amount of normal tissue, thereby protecting against radiated‐related esophageal, pulmonary, and cardiac injuries.

Under the current payment model, the cost of radiotherapy is based on the number treatments delivered. Although HFRT is reported to be more resource‐efficient and less costly compared with CFRT in patients with breast cancer and prostate cancer,[24](#cam42250-bib-0024){ref-type="ref"}, [25](#cam42250-bib-0025){ref-type="ref"}, [26](#cam42250-bib-0026){ref-type="ref"} to date no study has reported the economic value of preoperative HFRT in esophageal cancer. On comparing the time commitments and costs related to therapy, we found that preoperative HFRT can significantly shorten the durations of both radiotherapy and hospitalization (16.7 and 69.0 days, respectively) compared with CFRT (32.8 and 80.4 days, respectively) by requiring fewer fractions. Moreover, the HFRT schedule required fewer visits to radiation departments, making the approach much more convenient for patients from remote areas. When treatment is completed in a shorter time period, interruptions unrelated to treatment are also reduced, which may improve compliance. Finally, HFRT had significantly lower total and radiotherapy‐related costs compared with CFRT. Overall, our HFRT protocol was advantageous for both the patient and the institute, effectively reducing financial and treatment‐related burdens for both parties.

The limitation of this study was its retrospective nonrandomized design. The reason of applying two different fractionation schemes was because of the physicians\' preference. This may bring some selective bias to the selection of patients. Nevertheless, the current results justify randomized prospective clinical trials.

5. CONCLUSIONS {#cam42250-sec-0019}
==============

We conclude that HFRT has comparable efficacy to CFRT without increasing adverse effect rates or decreasing the pCR, PFS or OS; therefore, it can be recommended as a safe and effective alternative to CFRT for neoadjuvant radiotherapy in patients with esophageal cancer. HFRT requires fewer fractions, can be delivered in a shorter duration and costs less when compared with CFRT. Furthermore, a prospective randomised controlled study with a larger sample is warranted to assess the efficacy of the neoadjuvant HFRT protocol in the treatment of esophageal squamous cell carcinoma to establish HFRT as having a key role in neoadjuvant radiotherapy.
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